

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY
CONVEYING PARTY DATA	
Name	Execution Date
TOUCAN CAPITAL FUND II, L.P.	03/29/2012
RECEIVING PARTY DATA	
Name:	NORTHWEST BIOTHERAPEUTICS, INC.
Street Address:	120 Northgate Plaza
City:	Seattle
State/Country:	WASHINGTON
Postal Code:	98125
PROPERTY NUMBERS Total: 7	
Property Type	Number
Patent Number:	5788963
Patent Number:	5990294
Patent Number:	5874290
Patent Number:	6863887
Patent Number:	7087715
Application Number:	09016737
Application Number:	10789807
CORRESPONDENCE DATA	
Fax Number:	(973)596-0545
Phone:	9735964500
Email:	ipdocket@gibbonslaw.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Gibbons P.C.
Address Line 1:	One Gateway Center
Address Line 4:	Newark, NEW JERSEY 07102

CH \$280.00 5788963

ATTORNEY DOCKET NUMBER:	111262-79930
NAME OF SUBMITTER:	Robert E. Rudnick
Total Attachments: 3 source=Security#page1.tif source=Security#page2.tif source=Security#page3.tif	

RELEASE OF SECURITY INTEREST

WHEREAS, TOUCAN CAPITAL FUND II, L.P., with offices at 7600 Wisconsin Avenue, Suite 700, Bethesda, Maryland 20814, in 2004, entered into security agreements in and to those United States patents and United States patent applications set forth on Exhibit A attached hereto and made a part hereof (collectively the "Secured Patents"), and such security interests are still in place. In accordance with those certain Security Agreements as set forth on Exhibit A attached hereto (the "Security Agreements"), such Security Agreements were recorded with the United States Patent and Trademark Office as described on Exhibit A attached hereto (collectively, the "Security Interests"); and

WHEREAS, TOUCAN CAPITAL FUND II, L.P. has completed its operations;

NOW, THEREFORE, for good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, the Security Interests of TOUCAN CAPITAL FUND II, L.P. and all other rights of TOUCAN CAPITAL FUND II, L.P., if any, with respect to the Secured Patents, are hereby fully and irrevocably released.

DATE: March 29, 2012

TOUCAN CAPITAL FUND II, L.P.

By: Linda F Powers

Name: Linda F Powers

Title: Administrator

EXHIBIT A

1. United States patent titled ISOLATION AND/OR PRESERVATION OF DENDRITIC CELLS FOR PROSTATE CANCER IMMUNOTHERAPY, Patent No. 5,788,963, dated August 4, 1998 in accordance with that certain Security Agreement dated April 26, 2004, which Security Agreement was recorded with the United States Patent and Trademark Office at Reel 014567 and Frame 0206 on April 27, 2004.
2. United States patent titled ISOLATION AND/OR PRESERVATION OF DENDRITIC CELLS FOR PROSTATE CANCER IMMUNOTHERAPY, Patent No. 5,788,963, dated August 4, 1998 in accordance with that certain Security Agreement dated July 30, 2004, which Security Agreement was recorded with the United States Patent and Trademark Office at Reel 015093 and Frame 0483 on September 8, 2004.
3. United States patent titled NUCLEOTIDE AND AMINO ACID SEQUENCES OF C4-2, A TUMOR SUPPRESSOR GENE, AND METHODS OF USE THEREOF, Patent No. 5,990,294, dated November 23, 1999 in accordance with that certain Security Agreement dated April 26, 2004, which Security Agreement was recorded with the United States Patent and Trademark Office at Reel 014567 and Frame 0206 on April 27, 2004.
4. United States patent titled NUCLEOTIDE AND AMINO ACID SEQUENCES OF C4-2, A TUMOR SUPPRESSOR GENE, AND METHODS OF USE THEREOF, Patent No. 5,990,294, dated November 23, 1999 in accordance with that certain Security Agreement dated July 30, 2004, which Security Agreement was recorded with the United States Patent and Trademark Office at Reel 015093 and Frame 0483 on September 8, 2004.
5. United States patent titled NUCLEOTIDE AND AMINO ACID SEQUENCES OF A D2-2 GENE ASSOCIATED WITH BRAIN TUMORS AND METHODS BASED THEREON, Patent No. 5,874,290 dated February 23, 1999 in accordance with that certain Security Agreement dated April 26, 2004, which Security Agreement was recorded with the United States Patent and Trademark Office at Reel 014567 and Frame 0206 on April 27, 2004.
6. United States patent titled NUCLEOTIDE AND AMINO ACID SEQUENCES OF A D2-2 GENE ASSOCIATED WITH BRAIN TUMORS AND METHODS BASED THEREON, Patent No. 5,874,290 dated February 23, 1999 in accordance with that certain Security Agreement dated July 30, 2004, which Security Agreement was recorded with the United States Patent and Trademark Office at Reel 015093 and Frame 0483 on September 8, 2004.
7. United States patent titled THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE ROLE OF THE CXCR-4 GENE IN TUMORIGENESIS, Patent No. 6,863,887 dated March 8, 2005 in accordance with that certain Security Agreement dated April 26, 2004, which Security Agreement was recorded with the United States Patent and Trademark Office at Reel 014567 and Frame 0206 on April 27, 2004.
8. United States patent titled THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE ROLE OF THE CXCR-4 GENE IN TUMORIGENESIS, Patent No. 6,863,887 dated March 8, 2005 in accordance with that certain Security Agreement dated July 30, 2004, which

Security Agreement was recorded with the United States Patent and Trademark Office at Reel 015093 and Frame 0483 on September 8, 2004.

9. United States patent titled HUMAN PARIS-1 ANTIGEN AND NUCLEIC ACIDS: DIAGNOSTIC AND THERAPEUTIC USES, Patent No. 7,087,715 dated August 8, 2006 in accordance with that certain Security Agreement dated April 26, 2004, which Security Agreement was recorded with the United States Patent and Trademark Office at Reel 014567 and Frame 0206 on April 27, 2004.

10. United States patent titled HUMAN PARIS-1 ANTIGEN AND NUCLEIC ACIDS: DIAGNOSTIC AND THERAPEUTIC USES, Patent No. 7,087,715 dated August 8, 2006 in accordance with that certain Security Agreement dated July 30, 2004, which Security Agreement was recorded with the United States Patent and Trademark Office at Reel 015093 and Frame 0483 on September 8, 2004.

11. United States patent application titled ISOLATION AND/OR PRESERVATION OF DENDRITIC CELLS FOR PROSTATE CANCER IMMUNOTHERAPY, Patent Application No. 09/016,737 dated January 30, 1998 in accordance with that certain Security Agreement dated April 26, 2004, which Security Agreement was recorded with the United States Patent and Trademark Office at Reel 014567 and Frame 0206 on April 27, 2004.

12. United States patent application titled ISOLATION AND/OR PRESERVATION OF DENDRITIC CELLS FOR PROSTATE CANCER IMMUNOTHERAPY, Patent Application No. 09/016,737 dated January 30, 1998 in accordance with that certain Security Agreement dated July 30, 2004, which Security Agreement was recorded with the United States Patent and Trademark Office at Reel 015093 and Frame 0483 on September 8, 2004.

13. United States patent application titled GENERATION OF DENDRITIC CELLS FROM MONOCYTIC DENDRITIC PRECURSOR CELLS WITH GM-CSF IN THE ABSENCE OF ADDITIONAL CYTOKINES, Patent Application No. 10/789,807 dated February 27, 2004 in accordance with that certain Security Agreement dated April 26, 2004, which Security Agreement was recorded with the United States Patent and Trademark Office at Reel 014567 and Frame 0206 on April 27, 2004.

14. United States patent application titled GENERATION OF DENDRITIC CELLS FROM MONOCYTIC DENDRITIC PRECURSOR CELLS WITH GM-CSF IN THE ABSENCE OF ADDITIONAL CYTOKINES, Patent Application No. 10/789,807 dated February 27, 2004 in accordance with that certain Security Agreement dated July 30, 2004, which Security Agreement was recorded with the United States Patent and Trademark Office at Reel 015093 and Frame 0483 on September 8, 2004.